SYNERGISM BETWEEN A NOVEL AMPHIBIAN OOCYTE RIBONUCLEASE AND LOVASTATIN IN INDUCING CYTOSTATIC AND CYTOTOXIC EFFECTS IN HUMAN LUNG AND PANCREATIC-CARCINOMA CELL-LINES

被引:64
作者
MIKULSKI, SM [1 ]
VIERA, A [1 ]
DARZYNKIEWICZ, Z [1 ]
SHOGEN, K [1 ]
机构
[1] NEW YORK MED COLL,CANC RES INST,ELMSFORD,NY 10523
关键词
D O I
10.1038/bjc.1992.261
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A novel anti-tumour amphibian oocyte RNase, ONCONASE(R) (ONC), previously known as P-30 Protein, is in the clinical trials. The effect of ONC alone and in combination with lovastatin (LVT), an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, a rate-limiting enzyme of mevalonate (MVA) and cholesterol synthesis pathway, in three human tumour cell lines ASPC-1 pancreatic, A-549 lung, and HT-520 lung carcinomas, has been presently studied. A synergism between ONC and LVT in inducing the cytostatic and cytotoxic effects was observed. The cytostatic effect, seen during the early phase of the treatment with this combination of drugs was manifested as prolongation of the cell cycle duration, especially of the G1 phase; cell death was apparent after 72 h of treatment. The synergistic effect of ONC and LVT was also evident in the clonogenicity assays. Both LVT lactone and its in vitro activated beta-hydroxy acid form, alone and in respective combinations with ONC, exerted similar degree of growth suppression. The effects of both forms of LVT (used alone or in combination with ONC) were reversed by MVA, which suggests that HMG-CoA reductase inhibition is a primary mechanism of LVT action. The data indicate that the LVT lactone can be activated intracellularly by tumour cells studied, and that the combination of ONC with LVT can produce significantly enhanced anti-tumour activities.
引用
收藏
页码:304 / 310
页数:7
相关论文
共 47 条
[1]   TRANSFORMING RAS GENES FROM HUMAN-MELANOMA - A MANIFESTATION OF TUMOR HETEROGENEITY [J].
ALBINO, AP ;
LESTRANGE, R ;
OLIFF, AI ;
FURTH, ME ;
OLD, LJ .
NATURE, 1984, 308 (5954) :69-72
[2]  
ANDEREGG RJ, 1988, J BIOL CHEM, V263, P18236
[3]  
ARDELT W, 1991, J BIOL CHEM, V266, P245
[4]   RAS GENES [J].
BARBACID, M .
ANNUAL REVIEW OF BIOCHEMISTRY, 1987, 56 :779-827
[5]   CRITERIA FOR ANALYZING INTERACTIONS BETWEEN BIOLOGICALLY-ACTIVE AGENTS [J].
BERENBAUM, MC .
ADVANCES IN CANCER RESEARCH, 1981, 35 :269-335
[6]   AMINO-ACID SUBSTITUTIONS AT CODON-13 OF THE N-RAS ONCOGENE IN HUMAN ACUTE MYELOID-LEUKEMIA [J].
BOS, JL ;
TOKSOZ, D ;
MARSHALL, CJ ;
VERLAANDEVRIES, M ;
VEENEMAN, GH ;
VANDEREB, AJ ;
VANBOOM, JH ;
JANSSEN, JWG ;
STEENVOORDEN, ACM .
NATURE, 1985, 315 (6022) :726-730
[7]  
BRANDES LJ, 1987, CANCER RES, V47, P4025
[8]   CHANGES IN CELL-NUCLEI DURING S-PHASE - PROGRESSIVE CHROMATIN CONDENSATION AND ALTERED EXPRESSION OF THE PROLIFERATION-ASSOCIATED NUCLEAR PROTEINS KI-67, CYCLIN (PCNA), P105, AND P34 [J].
BRUNO, S ;
CRISSMAN, HA ;
BAUER, KD ;
DARZYNKIEWICZ, Z .
EXPERIMENTAL CELL RESEARCH, 1991, 196 (01) :99-106
[9]   P21RAS IS MODIFIED BY A FARNESYL ISOPRENOID [J].
CASEY, PJ ;
SOLSKI, PA ;
DER, CJ ;
BUSS, JE .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (21) :8323-8327
[10]   TUMORIGENIC TRANSFORMATION OF MAMMALIAN-CELLS INDUCED BY A NORMAL HUMAN-GENE HOMOLOGOUS TO THE ONCOGENE OF HARVEY MURINE SARCOMA-VIRUS [J].
CHANG, EH ;
FURTH, ME ;
SCOLNICK, EM ;
LOWY, DR .
NATURE, 1982, 297 (5866) :479-483